Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Brii Biosciences's Average Total Inventories for the quarter that ended in Dec. 2023 was HK$0.00 Mil. Brii Biosciences's Revenue for the
six
months ended in Dec. 2023 was HK$0.00 Mil.
Brii Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023
stayed the same
from Jun. 2023 (0.00) to Jun. 2023 (0.00)
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Brii Biosciences Inventory-to-Revenue Historical Data
The historical data trend for Brii Biosciences's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Brii Biosciences's Inventory-to-Revenue
For the Biotechnology subindustry, Brii Biosciences's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's Inventory-to-Revenue falls into.
Brii Biosciences Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Brii Biosciences's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Brii Biosciences's Days Inventory for the
six
months ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brii Biosciences Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Brii Biosciences's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Brii Biosciences (HKSE:02137) Business Description
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02137 has been successfully added to your 